SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Skin toxicity treatment in patients with advanced or metastatic colorectal cancer (mCRC) and
non-mutated (wild-type) KRAS treated with panitumumab monotherapy after failure of
fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Phase:
Phase 2
Details
Lead Sponsor:
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH